D.E. Shaw & Co
CMPX icon

D.E. Shaw & Co’s Compass Therapeutics CMPX Stock Holding History

D.E. Shaw & Co’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$349K Buy
65,967
+14,485
+28% +$83.6K ﹤0.01% 4017
2025
Q4 		$276K Buy
+51,482
New +$238K ﹤0.01% 4192

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co's CMPX Position: Q1 2026 in Review

D.E. Shaw & Co increased its Compass Therapeutics (CMPX) stake by 28% in Q1 2026, buying an estimated $83.6K and bringing the position to 65,967 shares worth $349K. The position accounts for ﹤0.01% of the portfolio, ranked #4017.

D.E. Shaw & Co first reported a position in CMPX in Q4 2025 and has held it in 2 quarters since. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • D.E. Shaw & Co held 65,967 shares of Compass Therapeutics worth $349K as of Q1 2026.
  • D.E. Shaw & Co bought 14,485 Compass Therapeutics shares in Q1 2026, an estimated $83.6K.
  • Compass Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #4017 holding.
  • D.E. Shaw & Co first reported a position in Compass Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.